United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

Key Terms

pah medical

Pulmonary arterial hypertension (PAH) is a chronic condition in which the small blood vessels that carry blood from the heart to the lungs become narrowed or stiff, raising pressure and forcing the heart to work harder—like trying to squeeze water through a narrowed garden hose. It matters to investors because drug development, clinical trial outcomes, regulatory approvals and pricing decisions for PAH therapies can create significant revenue opportunities or financial risks for biotech and pharmaceutical companies operating in this therapeutic area.

ipf medical

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease where scar tissue builds up in the lungs for reasons doctors don't fully understand, making it harder to breathe over time. For investors, IPF matters because it represents a clear medical need and a regulated market for treatments, so progress in clinical trials, regulatory approvals, or new therapies can materially affect the value of companies working on drugs or devices for this condition—much like a new road that could open access to a previously hard-to-reach town.

ph-ild medical

PH-ILD stands for pulmonary hypertension associated with interstitial lung disease, a condition where stiff or scarred lung tissue makes it harder to move oxygen into the blood and causes dangerously high blood pressure in the lung arteries. Investors care because it signals a serious, progressive illness with limited treatment options, shaping demand for therapies, clinical trial design, regulatory review and long-term revenue potential in respiratory and cardiovascular drug markets.

new drug application regulatory

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients with connective tissue disease, in which underlying vascular remodeling and endothelial dysfunction may be accelerated, making PAH more difficult to treat

TETON presentations include analyses showing that nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit compared to placebo in idiopathic pulmonary fibrosis (IPF) patients

Additional presentations feature interim data from the ARTISAN study of parenteral treprostinil in PAH patients and preliminary data from PHINDER, a first of its kind study designed to improve screening for pulmonary hypertension associated with interstitial lung disease (PH-ILD)

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four oral presentations and four poster presentations will be presented across its commercial and development portfolio at the European Society of Cardiology (ESC) Congress 2026, August 28-31 in Munich, and at the European Respiratory Society (ERS) Congress 2026, September 5-9 in Barcelona.

The presentations include late-breaking analyses from the phase 3 ADVANCE OUTCOMES study of investigational ralinepag in PAH, the phase 3 TETON clinical program evaluating nebulized treprostinil in IPF, and the ARTISAN study evaluating parenteral treprostinil in PAH, as well as preliminary data from the PHINDER study in PH-ILD.

“This year at ERS and ESC, we are presenting data that reflect the breadth of our work to deepen our understanding of how appropriate treatment may improve outcomes for people living with life-threatening diseases like PAH, PH-ILD, and IPF. We remain committed to generating meaningful evidence across both established and investigational therapies to help advance the standard of care for these patient populations,” said Franck Rahaghi, M.D., Chief Medical Officer, United Therapeutics.

ESC oral presentations

Treatment with Ralinepag Improves Outcomes in Patients with Connective Tissue Disease Associated with Pulmonary Arterial Hypertension: Results from the Phase 3 ADVANCE OUTCOMES Study
Late-breaking Oral Presentation, Saturday, August 29, 11:00 - 11:15 AM CEST. Presented by George Giannakoulas, M.D., Ph.D., Thessaloniki, Greece.

Early and Rapid Treprostinil Titration Improves Right Ventricular Ejection Fraction at 12 Months in Pulmonary Arterial Hypertension: ARTISAN Interim Analysis
Late-breaking Oral Presentation, Saturday, August 29, 12:00 - 12:15 PM CEST. Presented by Irene Marthe Lang, M.D., Vienna, Austria.

ERS oral and poster presentations

The Effect of Inhaled Treprostinil in Patients with Idiopathic Pulmonary Fibrosis Using a Win Ratio Analysis
Late-breaking Poster, PS-34, Abstract #PA824, Sunday, September 6, 8:00 - 9:30 AM CEST. Presented by Vincent Cottin, M.D., Ph.D., Lyon, France.

ARTISAN Interim Analysis: Early High-Dose Treprostinil Reduces mPAP and Improves Pulmonary Arterial Hypertension Risk Profile
Poster, PS-38, Abstract #PA910, Sunday, September 6, 8:00 - 9:30 AM CEST. Presented by Prof. Carmine Dario Vizza, Roma (RM), Italy.

Effect of Inhaled Treprostinil Dosing in Patients with Idiopathic Pulmonary Fibrosis Enrolled in the TETON IPF Program
Poster, PS-34, Abstract #PA833, Sunday, September 6, 8:00 - 9:30 AM CEST. Presented by Vincent Cottin, M.D., Ph.D., Lyon, France.

Clinical Improvement with Ralinepag in a Contemporary Pulmonary Arterial Hypertension Population: Insights from the ADVANCE OUTCOMES Study
Late-breaking Oral Presentation, 3K, Abstract #OA1218, Sunday, September 6, 9:30 – 10:45 AM CEST. Presented by Prof. Marc Humbert, M.D., Ph.D., Le Kremlin-Bicêtre, France.

Improvements in Lung Function Among Idiopathic Pulmonary Fibrosis Patients Treated with Inhaled Treprostinil
Oral Presentation, 3K, Abstract #OA3523, Monday, September 7, 11:00 AM - 12:15 PM CEST. Presented by Juergen Behr, Prof. Dr. med. München, Germany.

Limitations of Echocardiography for Pulmonary Hypertension Screening in Interstitial Lung Disease: Interim Results from the PHINDER Study
Poster, PS-37, Abstract #PA6317, Tuesday, September 8, 12:30 - 2:00 PM CEST. Presented by C.M. Thrasher, Pharm.D., M.A., Research Triangle Park, United States.

In June 2026, United Therapeutics submitted a New Drug Application for ralinepag to treat PAH, and a supplemental New Drug Application for nebulized treprostinil to treat IPF, to the FDA. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH. Nebulized treprostinil remains investigational for IPF.

About United Therapeutics

Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build. Visit us at www.unither.com and follow us on LinkedIn, Facebook, and Instagram.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others: our plans to generate meaningful evidence across both established and investigational therapies to help advance the standard of care for people living with life-threatening diseases like PAH, PH-ILD, and IPF; and our goals of expanding the supply of transplantable organs, developing practical technologies that can save lives, creating long-term shareholder value, and operating with sustainable practices. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of August 28, 2026, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260828683707/en/

Investor Inquiries
https://ir.unither.com/contact-ir

Media Inquiries
communications@unither.com

Source: United Therapeutics Corporation